

930 Wallace Ave.
Aptos, CA 95003

(831) 708-8799
www.sciopen.org

March 5, 2014

SciOpen Research Group, Inc. Annual Public Report

Mission

From the Bylaws, Article II Section 3:

“The specific purpose of this organization is to promote and facilitate research bridging basic scientific research to investigational therapeutics for amyotrophic lateral sclerosis (ALS). ALS is an invariably fatal disease for which no FDA approved treatment is currently regarded as effective at changing short or long term patient outcomes, to include slowing progression, reversing symptoms, or effectively curing a patient. The Organization will identify novel molecular entities with qualities applicable to ALS and will fund further development with the aim of delivering them into human clinical trial. “

This year SRG pursued its mission very well. We identified a novel molecule with clear applicability to ALS. The molecule, J147, has exciting possibilities for efficacy in ALS having previously shown remarkable results in an animal model of Alzheimer’s. Moreover, J147 exhibits pleiotropic effects, breaking it out of the box of the single-molecular target paradigm gripping neuroscience research.

With very few resources we established a presence then sought and obtained necessary partnerships and grants to enable the commencement of scientific testing of J147. We are currently seeking modest funding to enable histological tissue examination of the mice utilized in the survival study. Additionally, we have identified a possible future direction which would allow us to do crucial research utilizing amateur lab space. This gives a clear pathway toward future successful pursuit of our Mission.

SciOpen Research Group

Page 2 of 2

Project Status

SRG currently has three projects: J147, CNB-001, and fisetin. Through a series of successful negotiations, these projects are underway without the necessity of significant funding. We had a grant of nearly 100 mice from Prize4Life; 58 for J147 (according to protocol) and 36 extra which we are using in groups of 12 to get preliminary data on CNB-001 and fisetin, with one control group between them. SRG is planning to release a “crowdfunding” campaign to cover the costs of histological post-mortem tissue examination. The release of this campaign is currently imminent. It is targeted at \$30,000.00. We anticipate submission of the results of these projects for publication in the last quarter of 2014.

Having the expensive part of our first projects already underway without requiring us to produce significant funding was a blessing. The successful completion of the studies, with subsequent release of results in an Open-Access journal, would establish our ALS research model with direct results for the PALS community and public in general.

Progress In Reporting Year

This year saw SRG create itself from little more than a conversation and determination. Leveraging our Board members’ individual skills and reputations along with their business and social contacts, SRG not only created itself but produced its first working research project. We established a social media and web presence. We are well-poised for expansion of research projects.

Outlook For 2014

In 2013 SRG established itself and began negotiations which culminated in the commencement of its first research project. Along the way we established and/or enhanced relationships which can be crucial to our growth and development. Strategic relationships with new biolabs in California can allow us to take the next steps in the development of our model of “guerrilla biotech”. In 2014 we will finish our first research project and begin the process of publication of those results. That will bolster our standing as a serious research organization.

- Eric N. Valor

On behalf of the Board of Directors